Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Infusion in Severe Borderline Personality Disorder
NCT07099534Phase 2Not yet recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jan 2027
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in borderline personality disorder (BPD), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Borderline Personality Disorder Symptom Severity at Day 9. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT07099534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07099534.